Antigens

CancerVaccine™ target multiple antigen types and species in various cancer cells. It is not known what and how many cancer specific antigens occur in the heterogeneous population of enriched cancer stem cells. However, it is known that the same antigens can be in DNA, RNA and protein forms since antigens'mutant proteins are translated from the corresponding RNAs and the RNAs are transcribed from the corresponding DNA mutations. The triple confirmation of an antigen may be one of the most import steps for the antigen presentation processe. It is speculated that cancer cell specific antigens fall in the following categories:

  • Cancer specific peptides
  • Cancer specific proteins, including but not limited to: onco-proteins, lipoproteins, or carboxylated, phosphorylated, glycosylated or methylated proteins
  • Cancer specific DNA mutations
  • Cancer specific RNA mutations
  • Cancer specific metabolite mutations

It is not known which antigen is better, stronger or more effective in inducing immune responses. However, cancer researchers can compare immune responses induced by CancerVaccine™ with other antigens and determine:

  • For the same antigen, which form is the best? DNA, RNA, protein or the mixture of all. How do they compare with that of CancerVaccine™?
  • For multiple antigens, which way is the best? Banlanced with equal amount in each species or Balanced - Unbalanced with emphasis on one antigen, how do they compare with that of CancerVaccine™?
  • For irradiated whole cell cancer vaccines, how do the whole cell vaccine and fragments from the whole cancer cells compare with that of BioMedicure's CancerVaccine™?
  • For immune responses, how does antigen-loaded dendritic cell therapy compare with that of BioMedicure's CancerVaccine™ ?
  • For immune responses, how does antigen-loaded T-cell therapy compare with that of BioMedicure's CancerVaccine™ ?
  • For immune responses, how does antigen-loaded natural killer cell therapy compare with that of BioMedicure's CancerVaccine™ ?